Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Updates on the LINKER-MM1 Trial From AACR 2024 With Alankrita Taneja, MD, and Sundar Jagannath, MD

In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute. 

At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including the study design, which includes triple-class–refractory patients; the unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience; the response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients; management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections; the future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation; and more!

About Dr. Taneja and Dr. Jagannath

Alankrita Taneja, MD, is a Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Her research interests focus on the treatment of multiple myeloma, the use and development of cellular therapies, and humanism and equitable care.

Sundar Jagannath, MD, is a Professor of Medicine (Hematology and Medical Oncology) and the Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute in New York. He is a renowned expert in the research and treatment of multiple myeloma, with particular expertise in the development of novel therapeutics.

For More Information

Jagannath S, Richter J, Dhodapkar M, et al (2024). Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups. Presented at: 2024 American Association for Cancer Research Annual Meeting. Abstract CT001. Available at: https://www.abstractsonline.com/pp8/#!/20272/presentation/11419

Regeneron (2024). Linvoseltamab pivotal data presented at AACR reinforce high response rate that deepens over time in patients with heavily pre-treated multiple myeloma. Available at: https://investor.regeneron.com/news-releases/news-release-details/linvoseltamab-pivotal-data-presented-aacr-reinforce-high

Related Articles

Responses

Your email address will not be published. Required fields are marked *